Summary
Boston Scientific Corporation (BSX) has filed a Form 8-K on January 12, 2021, to announce preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2020. While the full financial details will be released in a subsequent filing, this preliminary information provides investors with an early look at the company's top-line performance heading into the new fiscal year. Investors should note that the information provided in this 8-K is preliminary and unaudited, and is subject to change as the company finalizes its financial statements. The press release attached as Exhibit 99.1 contains the substance of this filing, and investors should refer to it for the specific sales figures.
Key Highlights
- 1Boston Scientific announced preliminary sales results for Q4 and full year 2020.
- 2The filing was made on January 12, 2021, with results for the period ending December 31, 2020.
- 3The information provided is preliminary and unaudited.
- 4A press release detailing these results is attached as Exhibit 99.1.
- 5This filing serves to provide early top-line performance data to investors.
- 6The data is not considered 'filed' for Section 18 of the Exchange Act liabilities.
Frequently Asked Questions
The main purpose of this 8-K filing is to provide investors with preliminary, unaudited sales results for Boston Scientific's fourth quarter and full year ended December 31, 2020, ahead of their full financial reporting.
The specific preliminary sales figures are detailed in the press release issued by Boston Scientific on January 12, 2021, which is attached as Exhibit 99.1 to this 8-K filing.
No, the sales results disclosed in this 8-K filing are preliminary and unaudited. They are subject to change as the company completes its financial closing procedures and audits.
No, the information contained in Item 2.02 and Exhibit 99.1 of this filing is specifically stated as not being deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934, meaning the company is not subject to the liabilities associated with that section for this preliminary data.